How to buy Trillium Therapeutics stock | $17.91

Shares of Trillium Therapeutics jumped above $17 on Aug. 23 on word Pfizer would buy the Canadian drug developer in a $2.3 billion deal.

Trillium Therapeutics Inc is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around 0.00.

Trillium Therapeutics stock price (NASDAQ: TRIL)

Use our graph to track the performance of TRIL stocks over time.

Trillium Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-25.

Latest market close	$17.91
52-week range	$5.80 - $20.96
50-day moving average	$17.56
200-day moving average	$11.37
Wall St. target price	$19.88
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.50

Buy Trillium Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Trillium Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trillium Therapeutics price performance over time

Historical closes compared with the close of $17.91 from 2021-10-25

1 week (2021-10-20)	0.90%
1 month (2021-09-27)	1.02%
3 months (2021-07-27)	174.27%
6 months (2021-04-27)	94.25%

1 year (2020-10-27)	41.58%
2 years (2019-10-25)	6,548.11%
3 years (2018-10-26)	487.21%
5 years (2016-10-27)	25.24%

Trillium Therapeutics financials

Revenue TTM	$43,000
Gross profit TTM	$148,000
Return on assets TTM	-15.6%
Return on equity TTM	-29.91%
Profit margin	0%
Book value	$2.33
Market capitalisation	$1.9 billion

TTM: trailing 12 months

Shorting Trillium Therapeutics shares

There are currently 2.4 million Trillium Therapeutics shares held short by investors – that's known as Trillium Therapeutics's "short interest". This figure is 14.8% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting Trillium Therapeutics shares can be evaluated.

Trillium Therapeutics's "short interest ratio" (SIR)

Trillium Therapeutics's "short interest ratio" (SIR) is the quantity of Trillium Therapeutics shares currently shorted divided by the average quantity of Trillium Therapeutics shares traded daily (recently around 1.9 million). Trillium Therapeutics's SIR currently stands at 1.28. In other words for every 100,000 Trillium Therapeutics shares traded daily on the market, roughly 1280 shares are currently held short.

However Trillium Therapeutics's short interest can also be evaluated against the total number of Trillium Therapeutics shares, or, against the total number of tradable Trillium Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trillium Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Trillium Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Trillium Therapeutics shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trillium Therapeutics.

Find out more about how you can short Trillium Therapeutics stock.

Trillium Therapeutics share dividends

We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.

Have Trillium Therapeutics's shares ever split?

Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.

Trillium Therapeutics share price volatility

Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $5.8 up to $20.96. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9823. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Trillium Therapeutics overview

Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc.

Frequently asked questions

What percentage of Trillium Therapeutics is owned by insiders or institutions?
Currently 5.817% of Trillium Therapeutics shares are held by insiders and 84.933% by institutions. How many people work for Trillium Therapeutics?
Latest data suggests 33 work at Trillium Therapeutics. When does the fiscal year end for Trillium Therapeutics?
Trillium Therapeutics's fiscal year ends in December. Where is Trillium Therapeutics based?
Trillium Therapeutics's address is: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 What is Trillium Therapeutics's ISIN number?
Trillium Therapeutics's international securities identification number is: CA89620X5064 What is Trillium Therapeutics's CUSIP number?
Trillium Therapeutics's Committee on Uniform Securities Identification Procedures number is: 89620X100